Form 4: Galectin Therapeutics CEO Acquires Shares Through Deferred Stock Units
SEC Form 4 Filing
CEO Joel Lewis acquired 152,584 shares of Galectin Therapeutics through deferred stock units to satisfy compensation agreements.
Summary
- On March 1, 2024, Joel Lewis, the President and CEO of Galectin Therapeutics Inc., acquired 152,584 shares of common stock at a price of $1.96 per share.
- These shares were acquired through the settlement of deferred stock units (DSUs) as part of his compensation agreement.
- The transaction resulted in Mr. Lewis beneficially owning 897,716 shares of Galectin Therapeutics, including shares underlying DSUs and common stock.
- Shares were also withheld from issuance to Mr. Lewis for federal and state withholding taxes on income.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing simply reports a routine transaction related to executive compensation. There is no indication of positive or negative sentiment.
Positives
- The acquisition of shares by the CEO demonstrates his continued investment in the company.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the alignment of management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages often include deferred stock units to incentivize long-term performance and align executive interests with shareholder value.
- The vesting schedule of the DSUs (25% on March 1, 2023, 25% on September 1, 2028, and 50% on March 1, 2024) is a fairly standard approach to incentivizing long-term commitment.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock-based compensation as part of their executive pay packages.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the CEO's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| August 31, 2020 | Date of original employment agreement and Deferred Stock Unit Agreement between Mr. Lewis and Galectin Therapeutics Inc. |
| July 25, 2022 | Date of amendment to the Deferred Stock Unit Agreement. |
| March 1, 2023 | Date when twenty-five percent of DSUs were settled in shares of Common Stock. |
| March 1, 2024 | Date of the reported transaction where 152,584 shares were acquired through DSU settlement. |
| September 1, 2028 | Date when twenty-five percent of DSUs will be settled in shares of Common Stock. |
| March 4, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.